MILLER, DAVID,MACLEOD, ANGUS,VAN WILTENBURG, JIMMY,THOM, STEPHEN,ST-GALLAY, STEPHEN,SHANNON, JONATHAN
申请号：
CA3071145
公开号：
CA3071145A1
申请日:
2018.08.15
申请国别(地区):
CA
年份:
2019
代理人:
摘要：
The present invention relates to compounds of formula (I): Formula (I) wherein Q is selected from O or S； L is a saturated or unsaturated, optionally substituted C1-C12 hydrocarbylene group optionally including one or more heteroatoms N, O or S； R1 is -NR3R4, -OR5, -(C=NR6)R7, -(CO)R8, -CN, -N3, a quaternary ammonium group or an optionally substituted heterocycle； R3, R4, R5, R6, R7 and R8 are each independently hydrogen or a saturated or unsaturated, optionally substituted C1- C10 hydrocarbyl group optionally including one or more heteroatoms N, O or S； wherein optionally L and R3, or L and R4, or R3 and R4, or L and R5, or L and R6, or L and R7, or R6 and R7, or L and R8 together with the atom(s) to which they are attached may form a 3- to 12-membered, saturated or unsaturated, optionally substituted cyclic group； and R2 is a cyclic group substituted at the a-position, wherein R2 may optionally be further substituted； provided that the atom of L which is attached to the sulfur atom of the sulfonylurea group is a carbon atom and is not a ring atom of a heterocyclic or aromatic group. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.
